Significant progress on building a financially sustainable business, EBITDA improvement of 63.9%, Net loss improvement of 32.5% compared to 2013 on pro forma basis2014 Revenues through marketed products of EUR 28.1 million expected to be substantially increased in 2015 by acquired second commercialized vaccine Dukoral®Valneva’s key phase II and II/III clinical programs are proceeding towards important value inflection points towards the end of 2015Active progression on licensing activity for vaccines produced in EB66® underpinned by recent announcements
The Company expects its 2015 revenues to be significantly increased to between approximately EUR 75 and 85 million by its recent acquisition of the Dukoral® vaccine including a Nordic vaccine sales infrastructure and by revenue growth in its historical activities (revenue includes Dukoral® product sales by the seller’s group entities under transitional service agreement)
Revenues of IXIARO® product sales are expected to grow to approximately EUR 30 million
Valneva expects to continue to strive towards break-even following the transitional period of 2015 and the integration of the recently acquired business (2015 results may be significantly impacted by non-cash effects from acquisition accounting)
Within the next twelve months, Valneva expects important clinical results from its Pseudomonas aeruginosa vaccine phase II/III and its Clostridium difficile vaccine phase II studies which both have the potential to transform the value of the Company
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.